DCLK1 and cancer: DCLK1 isoforms 2 and 4 additionally possess a unique extracellular, non-kinase C-terminal binding region (NKEBD) that is targeted by therapeutic agents such as the monoclonal antibody CBT-15 to disrupt tumor–stromal interactions in cancer [27,28,29].